title: Prolonged response to aflibercept in ovarian cancer relapse: a case report.
abstract: VEGF-targeted therapies have shown activity in ovarian cancer, and one of them, bevacizumab, has been recently approved in this disease. Aflibercept is an antiangiogenic soluble fusion protein that inhibits VEGF-mediated signaling. In ovarian cancer, phase II trials with aflibercept have shown a significant benefit in the control of malignant ascites but with a lower response rate than expected.We report the case of a patient with relapsed ovarian cancer treated with aflibercept in fourth line, who experienced a prolonged response during more than two years with good tolerance. The duration of response to aflibercept was longer than that of the three previous lines of therapy (including the initial carboplatin-paclitaxel regimen) and ascites did not reappear. Further clinical research with this drug in ovarian cancer to identify patients who benefit most is warranted.
authors.affiliation: Medical Oncology Department, Hospital Universitario La Paz, Madrid - Spain.
authors.forename: Andrés
authors.initials: A
authors.lastname: Redondo
authors.forename: Beatriz
authors.initials: B
authors.lastname: Castelo
authors.forename: Alvaro
authors.initials: A
authors.lastname: Pinto
authors.forename: Pilar
authors.initials: P
authors.lastname: Zamora
authors.forename: Enrique
authors.initials: E
authors.lastname: Espinosa
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001201:Ascites / Q000209:etiology / Q000517:prevention & control; D016190:Carboplatin / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D065426:Cytoreduction Surgical Procedures; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D058990:Molecular Targeted Therapy / Q000379:methods; D020360:Neoadjuvant Therapy / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D016190:Carboplatin; D040262:Receptors, Vascular Endothelial Growth Factor; D017239:Paclitaxel